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Abstract
The effect of omeprazole on the mitochondrial carnitine/acylcarnitine transporter has been studied in proteoliposomes.
Externally added omeprazole inhibited the carnitine/carnitine antiport catalysed by the transporter. The inhibition was
partially reversed by DTE indicating that it was caused by the covalent reaction of omeprazole with Cys residue(s). Inhibition
of the C-less mutant transporter indicated also the occurrence of an alternative non-covalent mechanism. The IC50 of the
inhibition of the WT and the C-less CACT by omeprazole were 5.4 mM and 29 mM, respectively. Inhibition kinetics showed
non competitive inhibition of the WT and competitive inhibition of the C-less. The presence of carnitine or acylcarnitines
during the incubation of the proteoliposomes with omeprazole increased the inhibition. Using site-directed Cys mutants it
was demonstrated that C283 and C136 were essential for covalent inhibition. Molecular docking of omeprazole with CACT
indicated the formation of both covalent interactions with C136 and C283 and non-covalent interactions in agreement with
the experimental data.
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Introduction
Mitochondria represent important targets of pharmacological
compounds. Indeed, exogenous substances interacting with
mitochondrial enzymes or transporters may influence the entire
cell metabolism. Among many proteins which have been shown to
interact with pharmacological compounds [1], the carnitine/
acylcarnitine transporter (CACT) emerged as a target of drugs
[2,3]. The CACT has an essential role in the b-oxidation of fatty
acids [4]. From studies performed in intact mitochondria and in
proteoliposomes reconstituted with the purified or the recombi-
nant protein, the function of the transporter has been well
assessed. Physiologically, the transporter allows the entry of acyl
groups, as acylcarnitines, into the mitochondrial matrix, for the b-
oxidation. The free carnitine which is released in the matrix from
acylcarnitine is transported back to the cytosol by the same
transporter which catalyses an antiport reaction [4,5]. Inherited
defects of the CACT gene cause a syndrome which is known as
secondary carnitine deficiency [6] and is more severe than the
primary carnitine deficiency caused by defects of the plasma
membrane transporter OCTN2 [7]. The structure/function
relationships of the transporter have been well characterized and
several properties have been clarified using combined experimen-
tal approaches based on site-directed mutagenesis, chemical
targeting, functional analysis in proteoliposomes and bioinfor-
matics [8–11]. The transporter is functionally and structurally
asymmetrical and it is inserted in the proteoliposomal membrane
in a right-side out orientation as compared to mitochondria [12].
Thus the proteoliposome system is suitable for obtaining
physiologically relevant data, in absence of interferences by other
transporters or enzyme pathways. The CACT possesses 6 Cys
residues whose roles in the protein function have been defined
[9,13]. One of these residues, C136, is located in the middle of the
central cavity of the transporter and is responsible for the reactivity
with SH reagents, such as N-ethylmaleimide (NEM) which
inactivate the CACT. C155 can form a disulphide with C136
since, during some steps of the catalytic cycle, it comes close to
C136. C23 should be involved in the interaction with the
membrane, while C58 should interact with cardiolipin. C89 and
C283 seem to be less important for the protein function, even
though these residues are exposed in the upper level of the central
cavity. Due to the presence of several Cys residues, the CACT
may interact with pharmacological compounds exhibiting reac-
tivity towards thiol groups. Among the compounds with this
chemical property, omeprazole, has been well described in terms
of mechanism of pharmacological action. It reduces gastric
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secretion acting on the K+/H+-ATPase [14–18]. The pharmaco-
logical agent is activated at acidic pH in the gastric lumen and,
after chemical modifications, it becomes reactive towards an SH
group of the K+/H+-ATPase forming a mixed disulphide, which is
responsible of the inhibition of the proton pump. A similar
mechanism of interaction of omeprazole was also described for the
plasma membrane carnitine (OCTN2) transport system of rat
kidney. The drug causes inactivation of the transporter, by
forming mixed disulphides with Cys residues of the protein [19].
By analogy, the mitochondrial carnitine/acylcarnitine transporter
(CACT) may be a further potential target of omeprazole.
Interestingly it has been found that omeprazole strongly inhibits
the transport system. The structure/function relationships and the
mechanism of the interaction of omeprazole with the CACT have
been characterized by site-directed mutagenesis combined with
molecular docking.
Materials and Methods
Materials
Sephadexes G-50, G-75 and G-200 were purchased from
Pharmacia, L-[methyl-3H]carnitine 99% pure, 85 Ci/mmol, from
Scopus Research BV, Wageningen The Netherlands, egg-yolk
phospholipids (L-a-phosphatidylcholine from fresh turkey egg
yolk), 1,4-piperazinediethanesulfonic acid (Pipes), Triton X-100,
cardiolipin, L-carnitine and N-dodecanoylsarcosine (sarkosyl) from
Sigma-Aldrich. All other reagents were of analytical grade.
Site-directed mutagenesis, overexpression and isolation
of the CACT proteins
The previously constructed pMW7-WTratCACT recombinant
plasmid containing the wild-type (WT) CACT cDNA was used to
introduce the mutations in the CACT protein [12]. The amino
acid replacements were performed with complementary mutagen-
ic primers using the overlap extension method and the High
Fidelity PCR System (Roche). The PCR products were purified
and digested with NdeI and HindIII (restriction sites added at the
59 end of forward and reverse primers, respectively) and ligated
into the pMW7 expression vector. All mutations were verified by
DNA sequencing, and, except for the desired base changes, all the
sequences were identical to that of rat CACT cDNA. The
resulting plasmids were transformed into E. coli C0214. Bacterial
overexpression, isolation of the inclusion body fraction, solubili-
zation and purification of the wild-type CACT and mutant CACT
proteins were performed as described previously [12,20].
Reconstitution of wild-type and mutant CACT proteins in
liposomes
The recombinant proteins were reconstituted into liposomes as
described previously [12,20]. Briefly, a mixture was prepared with
60 mg protein, 1% Triton X-100, 10 mg phospholipids in the form
of sonicated liposomes, 10 mM Pipes pH 7.0 and 15 mM
carnitine in a final volume of 700 ml. The mixture was passed
15 times through the same Amberlite column (0.5 cm diameter x
3.2 cm height). The external substrate was then removed from
proteoliposomes on Sephadex G-75 columns before the transport
assay.
Transport measurements
Transport at 25uC was started by adding 0.1 mM [3H]carnitine
to proteoliposomes and terminated by the addition of 1.5 mM
NEM. In controls, the inhibitor was added together with the
labeled substrate, according to the inhibitor stop method [21,22].
This strategy allows subtracting, from the experimental samples,
the aliquot of radiolabelled carnitine diffusing through the
liposomal membrane. Finally, the external substrate was removed
by chromatography on Sephadex G-50 columns, and the
radioactivity in the liposomes was measured. The experimental
values were corrected by subtracting control values. For efflux
measurements, the proteoliposomes were loaded with radioactivity
before starting the transport assay. This was achieved by
incubating the proteoliposomes (600 ml), passed through Sephadex
G-75 as described in Materials and methods, with 5 mM
[3H]carnitine with a specific radioactivity of 10 nCi/nmol, for
60 min at 25uC. Then, the external radioactivity was removed by
passing again the proteoliposomes through Sephadex G-75 as
described above except that this chromatography was performed
at 4uC to minimize the loss of internal substrate during the
chromatography. Transport (efflux) was started by adding external
buffer or substrate and stopped at the appropriate time interval.
The transport assay temperature was 25uC. Finally, each sample
of proteoliposomes (100 ml) was passed through a Sephadex G-50
column to separate the external from the internal radioactivity.
Efflux activity was expressed as intraliposomal cpm. Activation of
omeprazole was obtained as follows: 25 mM omeprazole in
ethanol was diluted 10 fold in HCl 0.1 M and incubated for
15 min. Then, the pH was adjusted to pH 6.0 by Tris powder.
Molecular modeling, docking, and low-mode molecular
dynamics
CACT molecular model was built through the Swiss Model
server (http://swissmodel.expasy.org) after an alignment with the
bovine ADP/ATP carrier sequence. The alignment was inspected
and manually adjusted with the Deep View software [23], and the
output was used to run a SwissModel procedure in ‘Project Mode’.
Molecular docking was carried out with the Molecular
Operating Environment (MOE) 2011.10. A database of the
activated forms for protonic pump inhibitors (omeprazole,
pantoprazole and lansoprazole) was built through the Builder
module of MOE 2011.10. The structures were energy minimized
with the MMFF94x force field. The final structures were saved in
a database (mdb) file and then used for the molecular docking
simulations.
The CACT binding site was identified through the MOE Site
Finder module. This method is purely geometric and based not on
energy models but on alpha spheres, which are a generalization of
convex hulls [24]. Dummy atoms were positioned inside the
binding site in order to carry out a more focused molecular
docking procedure.
Docking was carried out with the MOE Dock program in its
standard ‘Rigid Receptor’ mode (with all the parameters set as
default). For each of the inhibitors bound to CACT, the top
scoring solutions, as ranked according to the GBVI/WSA dG
function, were selected. In order to optimize the interactions
between ligands and receptor and to compute the affinity through
the London dG empirical scoring function they were then
submitted to a further refinement through the MOE LigX
module. The dissociation constants for the complexes, expressed
as pKi (-Log Ki), were computed from the affinity data.
Low mode molecular dynamics (LowModeMD) was used to
generate putative conformations of CACT C89, C136, and C238
covalently bound to activated omeprazole. LowModeMD is aimed
at focusing a MD trajectory along the low-mode vibrations and
features a very efficient way versus classical MD for searching for
minima troughs on the potential energy surface. To run these
computations, we used the MOE Conformational Search
program. This program uses an efficient implicit method for
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estimating the low-frequency modes and is based on the
attenuation of high-range velocities, as described in detail in
[25]. A molecule of activated omeprazole was bound to C89 or
C136 or C238 in CACT with the MOE Builder. The omeprazole
atoms were left free to move during the LowModeMD, whereas
the residues more than 4.5 A˚ apart were fixed (not free to move,
but used for the energy calculations); the other residues were
defined as inert (fixed and not used for energy calculations). The
simulation was carried out with default parameters. Two hundred
and fifty structures were generated and ranked according to the
value of the potential energy of the conformation. The confor-
mations with strain energy lower than 2 kcal/mol versus the
lowest energy conformation were analyzed. One among the
conformations in which Cys238 was covalently bound to activated
omeprazole (conformation #5) was used to dock omeprazole,
according to the already described procedure.
Other methods
SDS-PAGE was performed as previously described [12]. The
amount of recombinant protein was estimated on Coomassie-blue
stained SDS-PAGE gels by using the Chemidoc imaging system
equipped with Quantity One software (Bio-Rad) as previously
described [26].
Results
Inhibition of the carnitine transporter by omeprazole
The effect of omeprazole on the carnitine transporter reconsti-
tuted in liposomes was investigated. The transport activity was
measured as 100 mM [3H]carnitine uptake into proteoliposomes
containing 15 mM carnitine, (carnitine/carnitine homologous
antiport) in the presence of externally added 30 mM omeprazole
activated by pre-incubation at pH 1.0 (see Materials and methods
and refs. [15–18]), or non activated, i.e. kept in a buffer at pH 7.0
before the use. The time course of the carnitine transport is shown
in Fig. 1. The accumulation of labeled carnitine into the
proteoliposomes depended on the time, it increased up to
4.2 mmol g protein21 at 60 min. 30 mM activated omeprazole
strongly inhibited the transport. At 10 min about 80% inhibition
was found. At 60 min the transport was still inhibited by about
85%; whereas the addition of the non-activated compound had no
inhibitory effect. The experimental data were interpolated in a first
order rate equation from which the initial rate of transport was
calculated as the product of the first order rate constant, k and the
transport at equilibrium. The initial transport rate in the presence
or absence of omeprazole was 0.30 or 0.045 mmol min21 g
protein21, respectively. The two forms of activated omeprazole
have functional groups [17] that could react with Cys residues of
the protein forming a mixed disulphide, as it was previously found
in the case of the gastric H+/K+-ATPase [16,17] and of the plasma
Figure 1. Effect of omeprazole on the carnitine antiport mediated by CACT. Transport was measured as described in Materials and methods
adding 0.1 mM [3H]carnitine at time zero to proteoliposomes containing 15 mM carnitine in the absence (#,.,m) or in the presence of activated (N,&) or non-activated (%) 30 mM omeprazole. In (.) 2 mM DTE was added 2 min before the transport start. In (n) 2 mM DTE was added 10 min after
the start to the proteoliposomes treated with omeprazole. In (,) the proteoliposomes were pre-incubated with omeprazole and passed through
Sephadex G-75 column to remove the non reacted reagent before the transport assay. The transport reaction was stopped at the indicated times, as
described in Materials and methods. Reported values are means 6 S.D. from three experiments of mmol of transported substrate per g of protein
(mmol ? g protein21).
doi:10.1371/journal.pone.0082286.g001
Figure 2. Dose-response curves for the inhibition of the
reconstituted WT and C-less CACT by omeprazole. The
carnitine/carnitine antiport rate was measured as described in Materials
and methods, adding 0.1 mM [3H]carnitine together with the indicated
concentrations of omeprazole to proteoliposomes reconstituted with
WT (N) or C-less (#) CACT. % residual activities with respect to the
control are reported. The values are means 6 S.D. from three
experiments.
doi:10.1371/journal.pone.0082286.g002
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membrane OCTN2 transporter [19]. SH group(s) of Cys of the
CACT are exposed towards the external side of the proteolipo-
somes, which corresponds to the cytoplasmic side of the
transporter [9,27]. These Cys could be involved in the mechanism
of inhibition by omeprazole via the formation of mixed
disulphide(s). To evaluate this hypothesis the effect of dithioery-
thritol (DTE), a disulphide reducing agent, was tested. The
addition of DTE to the proteoliposomes, after 10 min treatment
with activated omeprazole, led to partial recovery of the transport
function, which was clearly evident at 60 min of transport: about
78% of the activity was rescued respect to the inhibited sample. As
a control, DTE was added to the untreated protein; no
appreciable effects were observed. The incomplete recovery of
the transport function caused by DTE may indicate that only a
fraction of the transporter-omeprazole mixed disulphide linkage
was reversed by DTE or that omeprazole was also able to inhibit
the transporter by interactions different from the disulphide
formation. To ascertain the presence of non-covalent interaction,
the same experiment was performed on the C-less CACT, which
has an intrinsic activity lower than the WT [27] but sufficient for
evaluating the effect of the inhibitor. Indeed, omeprazole inhibited
also the C-less protein, even though at a lower extent respect to the
WT with a calculated initial rate of 0.051 mmol min21 g
protein21, i.e. 40% of that of C-less CACT in the absence of
omeprazole, 0.127 mmol min21 g protein21 (Fig. 1). No recovery
of transport function was exerted by the addition of DTE in the
case of the C-less CACT (not shown). This data indicated that the
compound interacted with the protein also in the absence of Cys
residues, i.e. non-covalently. To unequivocally demonstrate that
the inhibition observed on the WT protein was actually due to the
formation of mixed disulphide(s) between omeprazole and SH
residues of the protein, a strategy, previously described for other
transporters [3,19,28], was adopted. The proteoliposomes recon-
stituted with the wild type CACT were pre-incubated with
omeprazole and then passed through Sephadex G-75 columns to
remove the excess reagent. As shown in Fig. 1, the inhibition was
maintained after the Sephadex G-75 chromatography, indicating
that omeprazole was covalently bound (by mixed disulphide) to the
transporter. Since the formation of mixed disulphides should be
facilitated by alkaline pH, a similar experiment was performed at
pH 8.0, even though at this pH the CACT has a lower activity.
The extent of inhibition was nearly identical than that at pH 7.0
(not shown).
Kinetics of the inhibition of the carnitine transporter by
omeprazole
To characterize the effect of omeprazole caused by the two
different mechanisms of interaction with the transporter, kinetic
experiments were performed on the WT or C-less protein. The
dependence of the inhibition on the concentration of omeprazole
was studied. The antiport rate, measured as uptake of 100 mM
[3H]carnitine into proteoliposomes containing 15 mM carnitine,
was determined in the presence of increasing concentration of the
pharmacological agent. The dose response curves obtained are
shown in Fig. 2. Nearly complete inhibition of the transport was
observed with the WT at about 300 mM omeprazole; the
calculated IC50 from 3 experiments was 5.460.23 mM. In the
case of C-less protein maximal inhibition was observed at 1.8 mM
and the IC50 was 2968.5 mM. The same experiment was
performed on the WT, adding omeprazole to the proteoliposomes
in the presence of DTE. Under this condition i.e., the
pharmacological agent could not covalently bind the transporter
(see Materials and methods), the experimental data resembled
those obtained with the C-less protein (not shown). The IC50 of
the WT CACT were also determined for pantoprazole
(6.460.33 mM) and lansoprazole (80623 mM) (experiments not
shown). Inhibition kinetic studies were further performed on
Figure 3. Kinetic analysis of the inhibition of the reconstituted
CACT by omeprazole. The carnitine/carnitine antiport rate was
measured, as described in Materials and methods, adding [3H]carnitine
at different concentrations to proteoliposomes reconstituted with WT
CACT (A–C) or C-less CACT (B) containing 15 mM carnitine, in the
absence (#) or in the presence of external omeprazole to proteolipo-
somes. In A, B and C the respective omeprazole concentrations were: 5-
15–20 mM (N) and 10–40–68 mM (%). In C, 2 mM DTE was added
together with omeprazole. Experimental data plotted according to
Lineweaver-Burk as reciprocal transport rate vs reciprocal carnitine
concentrations. Reported values are means 6 S.D. from three
experiments of reciprocal of mmol of transported substrate per mg of
protein per min (min ? mg ? mmol21).
doi:10.1371/journal.pone.0082286.g003
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omeprazole to obtain data on the localization of the omeprazole
binding respect to the substrate binding site. The dependence of
the antiport rate on the external carnitine concentration was
studied in the absence or presence of activated omeprazole. The
data obtained on the WT and C-less CACT, analyzed in double
reciprocal (Lineweaver-Burk) plot are shown in Fig. 3. In the case
of WT (Fig. 3 A) the experimental data were interpolated by three
straight lines, which showed a common intersection point on the
abscissa. This behavior is typical of non-competitive inhibition.
The half saturation constant (Ki) for the inhibitor, derived from
the plot, was 10.661.6 mM (from three experiments). In the case
of the C-less protein (Fig. 3B), the data were interpolated by three
straight lines that, differently from the WT experiment, showed a
common intersection close to the ordinate, typical of a competitive
type of inhibition. The half saturation constant (Ki) for the
inhibitor, derived from the plot, was 29.561.2 mM, higher than
that obtained for the WT. Results similar to those obtained with
the C-less protein were observed on the WT in the presence of
DTE, with a Ki of 42.5614.9 mM (Fig. 3 C). In the case of
covalent inhibition, as that determined by omeprazole on the WT,
a non-competitive pattern could be obtained also if the inhibition
site is in the substrate binding site. This can be discriminated
studying the effect of protection of substrate on the inhibition as
described in Fig. 4. The incubation of the proteoliposomes with
30 mM omeprazole in the absence of carnitine led to inhibition of
4667%. If 1 mM or 15 mM carnitine was added before the
omeprazole, surprisingly, the inhibition increased to 80% and
92%, indicating that the omeprazole reaction with the transporter
was not protected but facilitated by the presence of carnitine. A
similar experiment was performed with other substrates of the
CACT which have higher affinity respect to carnitine, octano-
lylcarnitine (0.05–0.5 mM) and palmitoylcarnitine (0.02–0.1 mM).
Also the pre-incubation with these substrates increased the
inhibition extent to 57% and 74% in the case of octanolylcarnitine
or to 79% and 76% in the case of palmitoylcarnitine, respectively.
Identification of cysteine residues responsible for
omeprazole covalent inhibition
To identify the Cys residue(s) that could react with omeprazole,
the inhibition of Cys mutants of CACT lacking one or more Cys
residues was analyzed. All the mutants lacking only one of the Cys
residues were inhibited by more than 80% except the C136S,
which was inhibited by 59% and the C283A, which showed an
inhibition of 53% (Fig. 5). This indicated a major role of C136 and
C283 in the interaction with omeprazole. The results were
confirmed by the 54% inhibition of the mutant containing only
Figure 4. Effect of substrates on CACT inhibition by omeprazole. Carnitine (1 mM grey;15 mM white column), octanoyl-carnitine (oct-carn:
0.05 mM grey; 0.5 mM white column) or palmitoyl-carnitine (palm-carn: 0.02 mM grey; 0.1 mM white column) were added together with omeprazole
to proteoliposomes reconstituted with the WT CACT and previously passed onto a Sephadex G75 column to remove the external carnitine. After
5 min incubation un-reacted compounds were removed by passing the proteoliposomes through Sephadex G-75 as described in Materials and
methods. Transport was started adding 0.1 mM [3H]carnitine and stopped after 30 min. Percent residual activity is reported with respect to the
control without the addition of omeprazole. The data represent means 6 S.D. of three independent experiments. Significantly different from the
sample treated with omeprazole (white column-none) in the absence of substrates, as estimated by the Student’s t test (**p,0.01).
doi:10.1371/journal.pone.0082286.g004
Figure 5. Inhibition of WT and Cys mutants of CACT. Transport
rate was measured by adding 0.1 mM [3H]carnitine to proteoliposomes
and stopped after 30 min. Omeprazole 30 mM was added to the
proteoliposomes reconstituted with the various mutants and incubated
for 5 min. The un-reacted compound was removed by passing the
proteoliposomes through Sephadex G-75 as described in Materials and
methods. The % inhibition with respect to the control are reported. In
the legend the Cys residues substituted in the mutant proteins are
indicated. The values are means 6 S.D. from three experiments.
Significantly different from the WT CACT inhibited by omeprazole (WT
column), as estimated by the Student’s t test (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0082286.g005
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C136 (C-less/V136C) and lack of inhibition of the double mutant
C136/283S. As expected, also the C-less was not inhibited.
Investigation of omeprazole transport
According to the interaction of omeprazole with the substrate
binding site, the CACT might mediate the transport of
omeprazole. Since this transporter works by an antiport mode,
the transport of the pharmacological agent can be evaluated using
it as counter-substrate of [3H]carnitine. To this aim, proteolipo-
somes were loaded with [3H]carnitine by transporter-mediated
exchange equilibration (see Materials and methods). After this
procedure the proteoliposomes contained internal 15 mM
[3H]carnitine. In the absence of external substrate some efflux of
intraliposomal radioactivity was detected (Fig. 6), which was due to
the unidirectional transport activity of the CACT [29]. In another
set of experimental sample 0.15 mM carnitine was externally
added. This addition caused stimulation of the efflux due to the
induction of the antiport activity. The concentration of carnitine
was kept relatively low (0.15 mM) to be comparable with that of
omeprazole, the addition of which caused complete inactivation of
the transport activity. The addition of omeprazole together with
DTE, to prevent reaction with SH groups of the protein, led to
efflux of the same amount of radioactivity as in the case of absence
of external substrate. The data demonstrated that omeprazole
could not be transported from outside to inside the proteolipo-
somes in exchange for internal [3H]carnitine.
Molecular modeling
Molecular docking of omeprazole and also of pantoprazole and
lansoprazole demonstrated that these ligands can form stable
complexes with CACT through a set of non-covalent interactions.
The docking score was used to select the top scoring poses among
the 30 generated for each ligand. All the values were negative,
suggesting that these ligands can bind to CACT central cavity.
The computed dissociation constants (Ki) for the top scoring
complexes suggest the following rank of affinity towards CACT:
omeprazole . pantoprazole . lansoprazole (Tab. 1). For
omeprazole, which has been extensively characterized in the
reported experiments, we computed a Ki of approx. 22 mM. In
Figure 7B, a plot showing the CACT amino acids involved in
omeprazole molecular recognition are highlighted. Several basic
residues (K35, K135, R178, R219 and R275), two acidic residues
(E132 and D231), a cysteine (C136), and both some polar and
some apolar residues are clearly identified as interacting with
omeprazole. Very interestingly most of these residues were
previously found to be involved in the binding of substrate [30]
Three LowModeMD simulations were performed in order to
evaluate the possibility that activated omeprazole could covalently
bind to CACT cysteines, C89, C136 and C238. We analyzed 250
solutions for each simulation, and counted the number of solutions
with strain energy lower than 2 kcal/mol versus the conformation
with the lowest energy. We also evaluated the interaction potential
energies between omeprazole and CACT of the lowest energy
solutions for the three simulations (one for each of the studied
cysteines). From our computations, C283 seems the most likely to
covalently bind to omeprazole, since 9 conformations out of 250
showed a strain energy lower than 2 kcal/mol and the best
solution had an energy of 229.9 kcal/mol. An intermediate
reactivity can be hypothesized for C89, with 3 conformations
under 2 kcal/mol and potential omeprazole-CACT interaction
energy of 223.6 kcal/mol. The least reactive should be C136,
with just 2 solutions under 2 kcal/mol and potential omeprazole-
CACT interaction energy of 219.3 kcal/mol. From our in silico
results, all the investigated Cys could thus theoretically react with
activated omeprazole, forming covalent mixed disulphide bonds.
The proposed reactivity order is C283.C89.C136. C89 is,
however, excluded by the experimental data on CACT mutants.
On the basis of these observations, we selected one of the
generated solutions for CACT covalently bound to omeprazole on
C283, and we docked it with omeprazole. We obtained a set of 23
energetically favored (negative) solutions, with a top docking-score
of 26.64 kcal/mol for the non-covalently bound omeprazole
molecule. Through this procedure, we demonstrated the possibil-
ity that CACT could bind at the same time two omeprazole
molecules: one covalently bound to C283 and another non-
covalently bound inside the CACT central cavity. This solution is
depicted in Fig. 7A.
Figure 6. Effect of omeprazole on the carnitine efflux from proteoliposomes. Efflux of 15 mM [3H]carnitine from pre-labeled
proteoliposomes was measured as described in Materials and methods in the presence of only external 10 mM Pipes pH 7.0 (no addition),
omeprazole 0.15 mM, 5 mM DTE and carnitine 0.5 mM according to the legend added at time 0. The values are means 6 S.D. from three
experiments.
doi:10.1371/journal.pone.0082286.g006
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Discussion
In the present study, the proteoliposome system reconstituted
with the recombinant mitochondrial CACT has been used for
investigating the inhibition of the transporter by omeprazole. The
compound forms S-S mixed disulphide(s) with critical Cys residues
or week interactions with the substrate binding site, which are
observed as irreversible or competitive inhibition, respectively.
The WT transporter contains thiol groups of Cys exposed towards
the extraliposomal environment, which corresponds to the
cytosolic side of the transporter [9]. In this context the
pharmacological agent after activation by acidic pH as it occurs
physiologically in the gastric environment, could react covalently
with these Cys residues [14–16,18,31]. C283 and C136 have been
identified as targets of omeprazole, on the basis of data obtained
with mutant proteins. The two Cys residues are exposed in the
central cavity of the transporter, which face the extra-mitochon-
drial environment. C136 is in the bottom of the cavity just below
the substrate binding site and was previously found to be the main
target of small SH reagents such as NEM, which inactivate the
transporters; while C283 is located in the upper part of the cavity,
far from the carnitine binding site and is not involved in the
inhibition by SH reagents [9,20]. Omeprazole which is much
larger than NEM inhibits the transport upon binding to C283
causing steric hindrance and interferences with the translocation
process. The relatively high affinity of the transporter for
omeprazole (IC50 5.4 mM) should rely on the covalent bond
formation and also on several week interactions of hydrophobic
and aromatic groups of the compound with hydrophobic residues
of the CACT which are located in the neighborhood of C283, as
previously described [11]. The double mechanism of interaction is
also confirmed by the computational analysis, which predicts the
binding of omeprazole in the central cavity of the protein (Fig. 7A).
At an upper, more external level, the covalent binding with C283
is predicted for an omeprazole molecule. At a lower level the
binding of omeprazole in a non covalent mode is also predicted.
This location, which overlaps the substrate binding site, is in
agreement with the competitive interaction observed in the C-less
protein. Indeed, the computational analysis revealed that the
interaction of omeprazole with the transporter involves residues
which were previously found to constitute the substrate binding
site of carnitine [30]. The possible formation of a disulphide with
C136, placed just below the substrate binding site, is experimen-
tally demonstrated and fits very well with the positioning of
omeprazole in the lower level. Both methodologies concur to
indicate that omeprazole binds to C136 with lower efficiency
respect to C283 (see Results secion 3.5 and Fig. 4). Indeed, the
slightly lower inhibition of the mutant lacking C283 than of the
mutant lacking C136, indicates that this second covalent bond is
somewhat less efficient than that with C283; this is confirmed by
the finding that the mutant Cless-C136, containing the single
C136 residue, and the mutant C283S show the same extent of
inhibition (Fig. 4). Surprisingly, the covalent interactions of
omeprazole with the Cys residues involved in the inhibition are
facilitated by the presence of the substrate. This is explained by
conformational changes occurring in this moiety of the protein
upon substrate binding [11], which improves the accessibility of
C283. This also explains why the pre-incubation with omeprazole
produces a stronger inhibition compared to co-incubation during
transport assay as observed in Fig. 1. Indeed in pre-incubation
procedure the proteoliposomes have 15 mM external carnitine
which is then removed by Sephadex G-75 chromatography before
the transport assay (see Materials and methods). The similarity of
some aspects of the inhibition of the mitochondrial transporter
with those previously found for the plasma membrane OCTN2
transporter, which however were not described at the molecular
level [19], indicates that the substrate binding sites should have
some similar properties, in spite of the very different primary
structures and affinity for substrates of the two proteins. [11,32].
These similarities explain also the common interactions among the
two transporters and some drugs, such as b-lactam antibiotics,
Figure 7. Interaction of omeprazole with CACT. (A) Ribbon
representation of CACT with two bound molecules of omeprazole: one
covalently bound to C283, as computed through LowModeMD; another
non-covalently bound inside the CACT central cavity, as computed
through molecular docking on the top-scoring covalent complex
previously obtained thorugh LowModeMD. The molecular surface of
the protein, close to the ligands, is dotted in yellow. (B) ligand
interaction plot representing the CACT residues involved in omeprazole
molecular recognition. The depicted complex is the top-scoring one as
obtained through molecular docking. Associated docking score and
computed binding free energy are reported in Table 1. A caption
describing all the detected interactions is included in the picture.
doi:10.1371/journal.pone.0082286.g007
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previously described [3,33]. As it was reported for the OCTN2,
the IC50 of CACT for omeprazole is below the plasma
concentrations of the compound following the pharmacological
administration. To predict the possible in vivo implications of the
results described, it should be taken into account that the CACT
transporter is essential in most tissues for the process of fatty acid
b-oxidation. The defects of the CACT function, known as
secondary carnitine deficiencies, are characterized by encepha-
lopathy, respiratory distress, cardiomyopathy, muscle weakness,
myopathy, vomiting and others [34]. The inhibition by omepra-
zole may lead to a mild deficiency-like syndrome. This correlates
well with the symptoms like stomach pain, dizziness, difficult
breathing, muscle spasm, tightening and cramping, which are
described as side effects of omeprazole [see on the WEB: http://
dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id = 4761]. More-
over it has been demonstrated that omeprazole can enter the cells
in the activated form leading to toxicity at gastric level due to
oxidative damage caused by the interaction and oxidation of Cys
residues of proteins [31,35,36]. The mechanism of interaction with
the CACT could contribute to the oxidative damage as recently
found in the case of H2O2 [27].
In the light of the data presented, the described experimental
approach may have on the one hand utility for predicting side
interaction of pump inhibitor analogues with the CACT and,
hence, improve their safety. On the other hand such tools could be
useful for searching specific inhibitors of the CACT, which are of
interest, for example, as cardioprotective agents, as it was
previously described for mildronate which plays benefits under
ischemic conditions [2].
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